PPP2R5B

PPP2R5B

Overview

<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">PPP2R5B</th>
</tr>
<tr>
<td class="label">Symbol</td>
<td><strong>PPP2R5B</strong></td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>PPP2R5B</td>
</tr>
<tr>
<td class="label">Type</td>
<td>Gene</td>
</tr>
<tr>
<td class="label">NCBI</td>
<td><a href="https://www.ncbi.nlm.nih.gov/gene/?term=PPP2R5B" target="_blank">Search NCBI</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">1 edges</a></td>
</tr>
</table>

PPP2R5B (Protein Phosphatase 2 Regulatory Subunit B5 Beta) encodes the B56β (also known as B56β or PR53) regulatory subunit of protein phosphatase 2A (PP2A), one of the most abundant serine/threonine phosphatases in the brain. The PPP2R5B gene is located on chromosome 14q32.31 and encodes a protein of approximately 515 amino acids. This regulatory subunit plays a critical role in targeting PP2A to specific substrates, particularly those involved in tau phosphorylation, synaptic plasticity, and neuronal survival[@wang2016]. Dysregulation of PPP2R5B and resulting PP2A dysfunction is strongly implicated in the pathogenesis of Alzheimer's disease (AD), Parkinson's disease (PD), and other neurodegenerative disorders characterized by tau pathology and synaptic failure[@davidsson2020] [1](https://pubmed.ncbi.nlm.nih.gov/11239457/).

Gene and Protein Structure

PPP2R5B Gene Organization

PPP2R5B

Overview

<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">PPP2R5B</th>
</tr>
<tr>
<td class="label">Symbol</td>
<td><strong>PPP2R5B</strong></td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>PPP2R5B</td>
</tr>
<tr>
<td class="label">Type</td>
<td>Gene</td>
</tr>
<tr>
<td class="label">NCBI</td>
<td><a href="https://www.ncbi.nlm.nih.gov/gene/?term=PPP2R5B" target="_blank">Search NCBI</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">1 edges</a></td>
</tr>
</table>

PPP2R5B (Protein Phosphatase 2 Regulatory Subunit B5 Beta) encodes the B56β (also known as B56β or PR53) regulatory subunit of protein phosphatase 2A (PP2A), one of the most abundant serine/threonine phosphatases in the brain. The PPP2R5B gene is located on chromosome 14q32.31 and encodes a protein of approximately 515 amino acids. This regulatory subunit plays a critical role in targeting PP2A to specific substrates, particularly those involved in tau phosphorylation, synaptic plasticity, and neuronal survival[@wang2016]. Dysregulation of PPP2R5B and resulting PP2A dysfunction is strongly implicated in the pathogenesis of Alzheimer's disease (AD), Parkinson's disease (PD), and other neurodegenerative disorders characterized by tau pathology and synaptic failure[@davidsson2020] [1](https://pubmed.ncbi.nlm.nih.gov/11239457/).

Gene and Protein Structure

PPP2R5B Gene Organization

The PPP2R5B gene spans approximately 30 kb and consists of 14 exons encoding the B56β protein. The gene is part of a family of five PPP2R5 genes (A, B, C, D, E) that encode different B56 isoforms with distinct expression patterns and substrate specificities[@virshup2009] [2](https://pubmed.ncbi.nlm.nih.gov/11313136/). Alternative splicing generates additional variants with tissue-specific expression patterns.

B56β Protein Architecture

The B56β protein contains:

• N-terminal region: Contains the conserved B56 domain (~150 amino acids) responsible for substrate binding and PP2A targeting
• Central region: Contains multiple HEAT repeats involved in protein-protein interactions
• C-terminal region: Mediates interaction with the PP2A catalytic and scaffolding subunits

• Catalytic subunit (PP2AC/PPP2CA): The active phosphatase component
• Scaffold subunit (PPP2R1A/PR65A): Provides structural framework
• Regulatory subunit (B56β): Confers substrate specificity and subcellular localization

Biological Functions

Tau Dephosphorylation

One of the most critical functions of B56β-containing PP2A complexes in neurons is the dephosphorylation of the microtubule-associated protein tau. Tau is abnormally hyperphosphorylated in Alzheimer's disease, leading to its aggregation into neurofibrillary tangles (NFTs) and consequent synaptic and neuronal loss [4](https://pubmed.ncbi.nlm.nih.gov/15964256/).

B56β-PP2A dephosphorylates tau at multiple pathogenic sites including:

• Ser202/Thr205 (AT8 epitope): Critical for tau aggregation
• Thr212/Thr214: Associated with NFT formation
• Ser396: Major PHF-tau epitope
• Ser262/Ser356: Affects tau-microtubule binding

• Phosphorylation: B56β phosphorylation by kinases (e.g., CDK5, GSK3β) modulates its activity
• Methylation: PP2A methylation by PPME1 affects holoenzyme assembly
• Inhibition by endogenous inhibitors: Proteins like SET/TAF1β inhibit PP2A activity

Regulation of Kinase Signaling Pathways

B56β-PP2A regulates several key signaling pathways relevant to neurodegeneration:

Akt Signaling: PP2A dephosphorylates Akt at Ser473, terminating pro-survival signals and linking metabolic status to neuronal viability [5](https://pubmed.ncbi.nlm.nih.gov/18456421/).

MAPK/ERK Pathway: B56β-PP2A modulates ERK1/2 signaling, which is involved in synaptic plasticity and stress responses.

Wnt/β-catenin Pathway: PP2A-B56β dephosphorylates β-catenin, regulating its nuclear translocation and transcriptional activity in neuronal development and disease [6](https://pubmed.ncbi.nlm.nih.gov/14691019/).

Synaptic Function and Plasticity

PP2A-B56β is enriched at synapses where it regulates:

• AMPA receptor trafficking: PP2A modulates GluA1 phosphorylation and insertion
• NMDA receptor signaling: PP2A dephosphorylates NR2B subunits
• Long-term potentiation (LTP): PP2A activity is required for LTP maintenance
• Synaptic vesicle dynamics: PP2A regulates proteins involved in vesicle cycling

Apoptosis and Cell Survival

PP2A-B56β regulates apoptotic pathways by:

• Dephosphorylating pro-apoptotic proteins (e.g., BAD, BIM)
• Modulating p53 activity
• Regulating caspase activation
• Controlling mitochondrial permeability

Expression Pattern

Brain Expression

PPP2R5B is widely expressed in the human brain with highest levels in:

• Hippocampus (CA1-CA3 regions, dentate gyrus): Critical for memory circuits
• Cerebral cortex (layer II-IV): Sensory and associative areas
• Cerebellum: Motor coordination
• Substantia nigra: Dopaminergic neurons (relevant to PD)
• Basal forebrain: Cholinergic neurons

Cellular Localization

In neurons, B56β localizes to:

• Soma and dendrites: Colocalization with microtubules
• Synaptic compartments: Postsynaptic densities
• Nucleus: Regulation of nuclear signaling
• Cytoplasm: General phosphatase activity

Disease Associations

Alzheimer's Disease

PPP2R5B and PP2A dysregulation are strongly implicated in AD pathogenesis [8](https://pubmed.ncbi.nlm.nih.gov/24213635/):

PP2A Activity Reduction: Post-mortem studies show 30-50% reduction in PP2A activity in AD brain tissue compared to age-matched controls. This reduction correlates with disease severity and neurofibrillary tangle burden.

B56β Expression Changes: Altered B56β expression and distribution in AD brain, with decreased synaptic localization and increased cytoplasmic accumulation.

Tau Hyperphosphorylation: Reduced PP2A-mediated tau dephosphorylation directly contributes to NFT formation. Several pathogenic tau phosphorylation sites are PP2A substrates.

Synaptic Failure: PP2A-B56β dysregulation contributes to synaptic plasticity deficits that correlate with cognitive decline.

Mechanistic Links:

• Aβ oligomers can inhibit PP2A activity
• Neuroinflammation affects PP2A expression
• Tau pathology itself may impair PP2A function

Parkinson's Disease

PP2A dysfunction in PD involves:

• Dopaminergic neuron vulnerability: PP2A regulates survival of [dopaminergic neurons](/cell-types/vta-dopaminergic-neurons)
• α-Synuclein phosphorylation: PP2A can dephosphorylate pathogenic α-synuclein
• Mitochondrial function: PP2A regulates mitochondrial dynamics
• LRRK2 pathway: PP2A interacts with LRRK2 signaling

Other Neurodegenerative Disorders

Frontotemporal Dementia (FTD): Tau-positive FTD shows similar PP2A dysregulation Progressive Supranuclear Palsy (PSP): 4R tauopathies show PP2A alterations Amyotrophic Lateral Sclerosis (ALS): PP2A dysfunction in motor neurons

Cancer

B56 subunits including PPP2R5B can function as tumor suppressors. Loss of B56β expression has been reported in several cancers, and the gene may have context-dependent oncogenic or tumor-suppressive functions.

Therapeutic Implications

PP2A Activators as Therapeutic Strategy

Given the central role of PP2A dysfunction in neurodegeneration, PP2A activators are being explored as disease-modifying therapies:

Small Molecule Activators:

• Sodium selenate: Shown to activate PP2A and reduce tau pathology in animal models and clinical trials
• CGS-21680: A2A adenosine receptor agonist that activates PP2A
• Metformin: Activates PP2A through AMPK-dependent mechanisms

• PP2A methylation enhancers: Increase PP2A holoenzyme assembly
• Inhibitor antagonists: Block endogenous PP2A inhibitors like SET/TAF1β
• B56 subunit modulators: Enhance B56β expression or function

Biomarker Potential

PPP2R5B expression and PP2A activity measurements may serve as:

• Diagnostic biomarkers: Distinguish AD from other dementias
• Progression markers: Correlate with disease severity
• Therapeutic targets: Monitor treatment response

Genetics and Variants

Common Variants

Genome-wide association studies have identified potential associations between PPP2R5B variants and:

• Alzheimer's disease risk (ongoing research)
• Cognitive performance in aging
• Response to cholinesterase inhibitors

Rare Variants

Research is ongoing to identify rare pathogenic variants in PPP2R5B that may cause or modify neurodegenerative disease risk.

Molecular Mechanisms in Detail

Tau Dephosphorylation Cascade

The PP2A-B56β complex plays a central role in regulating tau phosphorylation through a coordinated dephosphorylation cascade. Under normal physiological conditions, PP2A-B56β maintains tau in a dynamic equilibrium between phosphorylated and dephosphorylated states, which is essential for microtubule stability and neuronal function.

The dephosphorylation process involves:

In Alzheimer's disease, this cascade is disrupted at multiple points:

• B56β expression is downregulated
• PP2A catalytic activity is reduced
• Endogenous inhibitors (SET, ARPP-19) are upregulated
• Post-translational modifications impair holoenzyme assembly

PP2A Regulation by Metals and Ions

PP2A activity is modulated by metal ions that can act as either activators or inhibitors:

Activators:

• Mg²⁺: Required for PP2A catalytic activity
• Mn²⁺: Can enhance phosphatase activity at physiological concentrations

• Aluminum (Al³⁺): Potent PP2A inhibitor, implicated in metal-induced neurodegeneration
• Lead (Pb²⁺): Inhibits PP2A and promotes tau hyperphosphorylation
• Copper (Cu²⁺): Complex regulation depending on concentration

Interaction with Neuroinflammation

PP2A-B56β intersects with neuroinflammatory pathways in complex ways:

Microglial Activation: Pro-inflammatory cytokines (IL-1β, TNF-α) can inhibit PP2A activity, creating a feed-forward loop where inflammation promotes tau pathology.

NLRP3 Inflammasome: PP2A dephosphorylates components of the inflammasome, potentially limiting inflammatory damage.

TNF-α Signaling: PP2A-B56β dephosphorylates key components of the NF-κB pathway, providing a brake on neuroinflammation.

Understanding these interactions may reveal novel therapeutic targets that address both tau pathology and neuroinflammation simultaneously.

Research Methods

Model Systems

• Cell lines: HEK293, SH-SY5Y neuronal cells
• Animal models: Transgenic mice with PP2A manipulation
• Induced neurons: iPSC-derived neurons from patients
• Post-mortem brain: Human brain tissue studies

Experimental Approaches

• Phosphatase assays: Measure PP2A activity toward tau substrates
• Western blotting: Analyze phosphorylation states
• Immunohistochemistry: Localize B56β in brain tissue
• Mass spectrometry: Identify PP2A substrates and interactions
• CRISPR: Genetic manipulation of PPP2R5B

Cross-Links

Related Genes and Proteins

• [PP2A catalytic subunit (PPP2CA)](/genes/ppp2ca) - PP2A catalytic component
• [PP2A scaffold subunit (PPP2R1A](/genes/ppp2r1a) - PP2A scaffolding
• [Tau (MAPT)](/proteins/tau) - PP2A substrate in AD
• [GSK3B](/genes/gsk3b) - Tau kinase counteracted by PP2A
• [CDK5](/genes/cdk5r1) - Tau kinase regulator
• [LRRK2](/genes/lrrk2) - PP2A interactor in PD

Related Mechanisms

• [Tau Pathology Pathway](/mechanisms/tau-pathology-pathway)
• [Protein Phosphatases in Neurodegeneration](/mechanisms/protein-phosphatases-neurodegeneration)
• [Synaptic Failure in AD](/mechanisms/synaptic-failure-pathway)
• [Apoptosis in Neurodegeneration](/mechanisms/apoptosis-neurodegeneration)
• [Neuroinflammation and Tau](/mechanisms/neuroinflammation-ad)

Related Diseases

• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease)
• [Progressive Supranuclear Palsy](/diseases/progressive-supranuclear-palsy)
• [Frontotemporal Dementia](/diseases/frontotemporal-dementia)

See Also

• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease)
• [Tau Proteins](/proteins/tau)
• [PP2A Signaling](/mechanisms/pp2a-signaling-pathway)

External Links

• [Ensembl: ENSG00000101443](https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000101443)
• [NCBI Gene: PPP2R5B](https://www.ncbi.nlm.nih.gov/gene/5524)
• [UCSC Genome Browser](https://genome.ucsc.edu/)

References